patients
PersonMentions
2
Relationships
3
Events
10
Documents
1
Also known as:
23,500+ patients
Parkinson's patients
23,500 patients
Stroke patients
Various Patients
Relationship Network
Loading... nodes
Interactive Network: Click nodes or edges to highlight connections and view details with action buttons.
Drag nodes to reposition. Node size indicates connection count.
Line color shows relationship strength: red (8-10), orange (6-7), yellow (4-5), gray (weak).
Use legend and help buttons in the graph for more guidance.
Event Timeline
Interactive Timeline: Hover over events to see details. Events are arranged chronologically and alternate between top and bottom for better visibility.
3 total relationships
| Connected Entity | Relationship Type |
Strength
(mentions)
|
Documents | Actions |
|---|---|---|---|---|
|
person
Rocchio
|
Professional |
5
|
1 | |
|
person
Rocchio
|
Professional clinical |
5
|
1 | |
|
person
Rocchio
|
Professional doctor patient |
5
|
1 |
| Date | Event Type | Description | Location | Actions |
|---|---|---|---|---|
| N/A | N/A | Stroke rehabilitation treatment program using imitation-based therapies. | Unspecified medical/researc... | View |
| N/A | N/A | ODYSSEY Phase 3 program: A comprehensive clinical trial program for PRALUENT, including 14 global... | Global | View |
| N/A | N/A | ODYSSEY Phase 3 program: A large-scale clinical trial program for the investigational LDL cholest... | Global | View |
| N/A | N/A | The ODYSSEY clinical trial program was conducted for the drug Praluent. | worldwide | View |
| N/A | N/A | Visit to Norman Geschwind's epilepsy clinic where he demonstrated symptoms of temporal lobe epile... | Epilepsy Clinic | View |
| N/A | N/A | ODYSSEY Phase 3 program: A comprehensive clinical trial program for an investigational LDL choles... | Global | View |
| N/A | N/A | ODYSSEY Phase 3 program | Global | View |
| 2025-12-01 | N/A | ODYSSEY clinical trial program. | N/A | View |
| 2016-01-01 | N/A | Projected clinical trials for Parkinson's patients. | California (implied) | View |
| 2012-05-01 | N/A | Outbreak of food poisoning involving more than 100 patients. | Upstate New York | View |
HOUSE_OVERSIGHT_026366.jpg
This document is a corporate communication and product information sheet for the prescription drug Praluent (alirocumab), manufactured by Sanofi. It details the ODYSSEY clinical trial program, provides important safety information for patients, and includes a legal disclaimer. The document is marked with the identifier 'HOUSE_OVERSIGHT_026366' but contains no information whatsoever related to Jeffrey Epstein, his associates, finances, or travel.
Corporate communication / product information sheet
2025-11-19
Total Received
$0.00
0 transactions
Total Paid
$105.00
3 transactions
Net Flow
-$105.00
3 total transactions
| Date | Type | From | To | Amount | Description | Actions |
|---|---|---|---|---|---|---|
| N/A | Paid | patients | Dr. Spencer | $5.00 | Starting price for procedures. | View |
| N/A | Paid | patients | Dr. Spencer | $100.00 | Maximum price charged for procedures. | View |
| N/A | Paid | patients | Narrator | $0.00 | Offers of money for referrals which were refused. | View |
As Sender
0
As Recipient
0
Total
0
No communications found for this entity. Entity linking may need to be improved.
Discussion 0
No comments yet
Be the first to share your thoughts on this epstein entity